News room > News archive
The Archives
Dear Viewer, This page is reserved for storing announcements of the previous calendar years and is currently stocked with content from CY 2014. All announcements for CY 2014 can be viewed on the announcements page.
22 November 2012-Section 708A(5)(e) Disclosure Notice
Cleansing Notice of issue of new ordinary shares to Tissue Therapies' consultant
22 November 2012-Appendix 3B
Issue of new ordinary shares to Tissue Therapies' consultant
Results AGM 2012
Results of the resolutions passed at the AGM 2012
30 Oct 2012-Appendix 4C Quarterly Report
Appendix 4C Quarterly Report, for the period 1 July to 30 September 2012.
30 Oct 2012- Device classification confirmed
The (MHRA) review of VitroGro® ECM has confirmed classification of VitroGro® ECM as a Medical Device Class 3, but under Device Rule 13, not Rule 8.
Proxy Form For Annual General Meeting
The Proxy form for the annual general meeting is provided here for your convenience
Notice of Annual General Meeting
The notice of annual general meeting is provided here for your convenience.
Annual Report 2011-12
During the 2011-12 financial year, some of the most important final milestones necessary for the sales launch of VitroGro® ECM were successfully completed. Please download the report for details.
30 Aug 2012-Cleansing notice
Issue of securities to Aslog Holding Limited.
29 Aug 2012-Appendix 3B
New issue announcement for strategic investor
29 Aug 2012-Private Placement to Strategic Investor
Tissue Therapies Limited is very pleased to announce that a new strategic investor has joined the Company’s share register via a private placement.
21 Aug 2012-Appendix 4E
Preliminary final report to the Australian Securities Exchange.
20 June 2012-Appendix 3B
Issue of new ordinary shares to Tissue Therapies consultants.
19 June 2012-Appendix 3B
Issue of new options to key Tissue Therapies staff and contractors.
1 June 2012-CE Marking Progress
Tissue Therapies advises that it will provide additional information to the Notified Body assessing the Company’s application for CE Marking of its initial product, VitroGro® ECM.
25 May 2012-Director Appointment and Resignation
Tissue Therapies announces the resignation of Greg Baynton as Director and the appointment of Iain Ross as Director.
2 May 2012-Response to ASX Price query
Tissue Therapies responds "No" to price query.
20 April 2012-Section 708A(5)e Disclosure Notice
Issue of new ordinary shares to Tissue Therapies consultants.
20 April 2012-Appendix 3B
Issue of new ordinary shares to Tissue Therapies consultants.
19 April 2012-Appendix 4C (quarterly)
Quarterly financial report for Tissue Therapies Limited.
30 March 2012-Appendix 3B
Ordinary shares issued on exercise of options previously issued under the Tissue Therapies equity option plan.
28 March 2012-Appendix 3B
Ordinary shares issued on exercise of options previously issued under the Tissue Therapies equity option plan.
27 April 2012-VitroGro Sales Planned to Start in June 2012
Tissue Therapies Limited is pleased to confirm that the final submission for CE Mark approval has been lodged.
8 Feb 20111-Half Year Accounts
Tissue Therapies has today confirmed that all milestones are on track for the start of VitroGro sales in early June 2012 in the UK and Europe.
24 Jan 2012-Appendix 4C (quarterly)
Quarterly financial report for Tissue Therapies Limited.